{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-117173","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.006919+00:00","generated_at":"2026-05-16T15:47:28.255672+00:00","sec_items":["1.01","2.01","2.03","3.02","5.01","5.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Apimeds Pharmaceuticals US completes merger with MindWave Innovations, issues 90.9% equity to MindWave holders","bullets":["On Dec 1, 2025, Apimeds (APUS) merged with MindWave Innovations, with MindWave surviving as wholly owned subsidiary.","MindWave stockholders received 29.9% of Apimeds common stock and 61% convertible preferred (as-converted), totaling 90.9% of post-merger equity.","Apimeds entered a $120.9M convertible note financing with 8% OID, issuing senior convertible notes.","CEO Erik Emerson resigned, replaced by Dr. Vin Menon; two new directors appointed.","Apimeds will effect a 1-for-10 reverse stock split and increase equity plan shares to 2,096,679."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-117173","json":"https://secwatch.observer/filing/0001213900-25-117173.json","markdown":"https://secwatch.observer/filing/0001213900-25-117173.md","text":"https://secwatch.observer/filing/0001213900-25-117173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025117173/0001213900-25-117173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025117173/ea0267807-8k425_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T15:47:28.255672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f150c14594f9295cc97bc5f9347be5b40639c92","claim":"Apimeds Pharmaceuticals US, Inc. issued 712,880 shares of Acquiror Common Stock of warrant to E.F. Hutton & Co. LLC for Underwriting/placement agent services.","evidence_excerpt":"On December 1, 2025, the Acquiror issued a warrant to E.F. Hutton & Co. LLC, to purchase 712,880 shares of Acquiror Common Stock","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025117173/0001213900-25-117173-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"712,880 shares of Acquiror Common Stock"},{"label":"Purchaser","value":"E.F. Hutton & Co. LLC"},{"label":"Consideration","value":"Underwriting/placement agent services"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}